Kloten ZH – NewcelX has received an investment of up to 3.4 million dollars, of which 1.35 million in cash and up to 2 million from the exercise of warrants. The funds will flow into the program for the potential cure of type 1 diabetes of the Zurich-based company, which was formed from a merger at the end of 2025.
(CONNECT) NewcelX strengthens its balance sheet with a private investment of 1.35 million dollars. The financing concluded in April 2026 and now announced on the occasion of the publication of its 2025 financial results also provides for additional potential proceeds of around USD 2 million from the future exercise of warrants. This financial transaction therefore involves up to 3.4 million dollars. According to the announcement by the Kloten-based company, which is listed on the NASDAQ, it also has access to its equity line of credit in the amount of 25 million dollars. It was "essentially" debt-free at the end of the year.
NewcelX was formed on October 30, 2025 from the merger between NLS Pharmaceutics Ltd. from Zurich and Kadimastem Ltd. from Nes Ziona, Israel. NewcelX is a clinical-stage regenerative medicine company developing stem cell-based therapies. Its flagship product NCEL-101 is a stem cell-derived islet cell therapy for insulin-dependent type 1 diabetes.
Dr. Julien Boisdron, a diabetes expert appointed to the Scientific Advisory Board at the beginning of January 2026 and Medical Director at Roche, will advise NewcelX on the further development of NCEL-101 towards clinical trials. To this end, NewcelX will reportedly continue to work closely with Eledon Pharmaceuticals from Irvine, California, in the current year.
"We are convinced that our scalable platform for the derivation of islet cells from stem cells in combination with targeted immune protection represents one of the few differentiated approaches for a potential functional cure for type 1 diabetes," Ronen Twito, Executive Chairman and CEO of NewcelX, is quoted as saying. "With our first annual results after the merger, the strengthened capital structure and the increasing scientific validation, we expect 2026 to be a year of significantly accelerated implementation." ce/mm
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Turnstile. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information